Table 1.
Patient and transplant characteristics
| Patient characteristics (n = 29) |
Transplant characteristics (n = 28) |
||
|---|---|---|---|
| Gender | Patients proceeding to HCT | 28 | |
| Male | 16 | HCT within 30 days of clofarabine | 26 |
| Female | 13 | Days clofarabine to conditioning (median) | 14 |
| Median age, years | 51 | (range) | (11–68) |
| Range | (23–69) | Days clofarabine to HCT (median) | 21 |
| Disease/disease state | (Range) | (17–75) | |
| ALL | 2 | Donor | |
| REL1 | 1 | Matched related | 11 |
| REL2 | 1 | Matched unrelated | 12 |
| MPD | 3 | Haploidentical + cord blood | 5 |
| MDS | 8 | Source | |
| Therapy related MDS | 1 | Peripheral blood | 22 |
| Prior response to hypomethylator | 0 | BM | 1 |
| AML | 16 | Cord blood | 5 |
| PIF | 9 | Conditioning regimen: | |
| REL1 | 6 | CLofarabine/melphalan/alemtuzumab | 3 |
| REL2 | 1 | Fludarabine/BU/ alemtuzumab | 2 |
| Refractory to last therapy | 12 | Fludarabine/melphalan/ alemtuzumaba | 17 |
| Therapy related AML | 2 | Fludarabine/melphalan/ ATG | 5 |
| Antecedent MDS | 3 | TBI/etoposide | 1 |
| Marrow blast%, median (n = 16) | 40 | TBI/etoposide/alemtuzumab | 1 |
| Range | (7.5–86) | GVHD prophylaxis | |
| Peripheral blood blast%, median (n = 16) | 3.5 | Tacrolimus/alemtuzumaba | 23 |
| Range | (0–81) | Tacrolimus/MMF/ATG | 5 |
| Cytogenetic risk group at diagnosis | Tacrolimus/MMF | 1 | |
| Adverse | 16 | CMV serostatus | |
| Intermediate | 12 | Recipient and/or donor positive | 18 |
| Favorable | 0 | Recipient and donor negative | 10 |
| HCT-comorbidity index, range | (0–5) | Donor gender (adult only) | |
| Low (0) | 16 | Female | 8 |
| Intermediate (1–2) | 6 | Male | 15 |
| High (3 or more) | 7 | Median donor age (adult only) | 41 |
| Prior treatment | (Range) | (21–72) | |
| None | 2 | ||
| 1 Prior regimen | 10 | ||
| 2 Prior regimens | 9 | ||
| 3 Or more prior regimens | 8 |
Abbreviations: CMV = cytomegalovirus; HCT = hematopoietic cell transplant; MDS = myelodysplastic syndrome; MPD = myeloproliferative disorder; PIF = primary induction failure; REL1 = first relapse; REL2 = second relapse. REL1, REL2, PIF, chronic phase (CP), accelerated phase (AP), MPD, CML, conditioning regimens have all been previously reported and included: fludarabine 30 (FLU) mg/m2/day i.v. on day − 7 through − 3 + melphalan (MEL) 140 mg/m2 on day –2 + alemtuzumab (ALEM) (100mg total) on day − 7 through − 3; clofarabine (CLO) 30 mg/m2/day i.v. on day − 7 through − 3 + MEL 140 mg/m2 on day −2 + ALEM (100mg total) on day − 7 through − 3; FLU mg/m2/day i.v. on day − 7 through − 3 + BU 3.2 mg/kg/day i.v. on day −6 through −3 (BU) + ALEM (100mg total) on day − 7 through − 3; TBI 1200 cGY + etoposide 60 mg/kg i.v. on day − 3 ± ALEM (100 mg total) on day − 7 through −3 for ALL patients; or FLU on day − 7 to − 3 + MEL 70 mg/m2/day i.v. on day −3 to − 2 + rATG 1.5 mg/kg i.v. (6 mg/kg total) on day − 7, − 5, − 3, − 1 (flu/mel/ATG) for cord blood recipients. All cord blood units were supplemented with additional CD34-selected haplo-identical related adult peripheral blood stem cells.
Includes patient that did not receive transplant.